1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Drug Pricing

Leaks And Prejudice Must End In US Multi-State Pricing Case

 
• By Dave Wallace

A host of leading generics firms have banded together to call for an order to prevent leaks and potentially harmful public allegations, as they confront ongoing multi-district litigation over generics pricing in the US.

Shhh
Leaks and allegations must be silenced, the firms say • Source: Shutterstock

In a filing that reads like a Who’s Who of top generics firms, more than a dozen companies have asked a Pennsylvania district court to intervene with an order to stop parties to a multi-state lawsuit over generics pricing from leaking information and releasing prejudicial information to the press.

Apotex, Aurobindo, Citron, Dr Reddy’s and Glenmark are among the companies filing the request, along with Lannett, Lupin, Mayne Pharma, Mylan and Endo’s Par

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Governor Newsom Expands Discounted Naloxone Availability To All Californians

 
• By Adam Zamecnik

After the product’s initial launch in May 2024, California’s government has now expanded the availability of its CalRx-branded generic OTC Narcan to all of its citizens.

Optum Rx Remodels Payment Model To Favor Generics – A Peace Offering For FTC?

 
• By Urtė Fultinavičiūtė

Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Walmart Pursues Generics Industry Leaders Over Price-Fixing

 
• By Dave Wallace

Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.

More from Policy & Regulation

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Medicines UK Welcomes NHS England’s Best-Value Biologics Biosimilar Adoption Framework

 
• By Adam Zamecnik

Reflecting on recent initiatives by NHS England and the MHRA, the newly renamed trade body Medicines UK has welcomed efforts in promoting the use of biosimilars in Britain.